Analysis of the therapeutic gain in the treatment of human osteosarcoma microcolonies in vitro with 211at-labelled monoclonal antibody

ABSTRACT Microcolonies were obtained by culturing cells of two human osteosarcoma lines (OHS and KPDX) and one human melanoma line (WIX-c) for either 24 or 72 h. The microcolonies were

treated with either alpha-particle radiation emitted by the 211At-labelled monoclonal antibody (MAb) TP-3 or external beam X-rays. Survival of microcolonies was assayed by colony formation.

Therapeutic gain factor (TGF) values were calculated for two survival levels, 50% and 20% microcolony regeneration (i.e. at least one cell in 50% or 20% of the colonies survived the

treatments). The TGF values were affected by the specific activity of the 211At-MAb conjugate, the antigen expression of the cells and the size and growth pattern of the microcolonies.

Treatment with 211At-TP-3 gave TGF values that varied from 1.3 +/- 0.4 to 4.5 +/- 0.7 (mean +/- s.e.). The antigen-rich OHS cell line had on average 1.6 times higher TGF than the

antigen-poor KPDX cell line. The TGF increased significantly with colony size for the densely packed colonies of the KPDX cell line but not for the OHS cell line, which had colonies with

cells growing in a more scattered pattern. Control experiments with the two non-specific 211At forms, free 211At and 211At-labelled bovine serum albumin, gave TGF values from 0.6 +/- 0.1 to

1.0 +/- 0.3. This study suggests that in vivo evaluation of 211At-MAbs using relevant tumour models is desirable. Access through your institution Buy or subscribe This is a preview of

subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 24 print issues and online access $259.00 per year only

$10.79 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout

ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS CARBON MINIBEAM RADIATION

THERAPY RESULTS IN TUMOR GROWTH DELAY IN AN OSTEOSARCOMA MURINE MODEL Article Open access 01 March 2025 EFFICACY AND SAFETY OF JMT103 IN PATIENTS WITH UNRESECTABLE OR SURGICALLY-CHALLENGING

GIANT CELL TUMOR OF BONE: A MULTICENTER, PHASE IB/II STUDY Article Open access 05 November 2024 EFFICIENT BONE MARROW IRRADIATION AND LOW UPTAKE BY NON-HAEMATOLOGICAL ORGANS WITH AN

YTTRIUM-90-ANTI-CD66 ANTIBODY PRIOR TO HAEMATOPOIETIC STEM CELL TRANSPLANTATION Article Open access 12 June 2024 AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Department of Chemistry,

University of Oslo, Norway RH Larsen Authors * RH Larsen View author publications You can also search for this author inPubMed Google Scholar * ØS Bruland View author publications You can

also search for this author inPubMed Google Scholar * P Hoff View author publications You can also search for this author inPubMed Google Scholar * J Alstad View author publications You can

also search for this author inPubMed Google Scholar * EK Rofstad View author publications You can also search for this author inPubMed Google Scholar RIGHTS AND PERMISSIONS Reprints and

permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Larsen, R., Bruland, Ø., Hoff, P. _et al._ Analysis of the therapeutic gain in the treatment of human osteosarcoma microcolonies _in vitro_

with 211At-labelled monoclonal antibody. _Br J Cancer_ 69, 1000–1005 (1994). https://doi.org/10.1038/bjc.1994.196 Download citation * Issue Date: 01 June 1994 * DOI:

https://doi.org/10.1038/bjc.1994.196 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not

currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative